Product Details

Long non-coding RNAs (lncRNAs), defined as RNA molecules over 200 bases with no protein-coding capacity, exhibit lower abundance, nucleus residency, tissue-specificity, and poor interspecies sequence conservation compared to mRNAs. Despite unknown functions, their increasing characterization suggests pivotal roles in gene expression regulation at transcriptional and post-transcriptional levels, impacting development, differentiation, and human diseases. Dysfunctional lncRNAs are linked to various diseases, from cancers to non-cancerous conditions. Creative Biogene offers complete solutions for analyzing LncRNA panels in 96- or 384-well qPCR arrays. Committed to affordability and quality, Creative Biogene aims to provide the most cost-effective and high-quality lncRNA qPCR arrays for your satisfaction.

Key Features of Our LncRNA qPCR Arrays

• Broad Applicability: Suitable for multiple species, including Homo sapiens, Mus musculus, Rattus norvegicus, and customizable for others upon request.
• Versatile Compatibility: Compatible with a wide range of qPCR instruments, ensuring flexibility in experimental setups.
• Rapid Analysis: Provides fast and convenient results, saving valuable research time.
• Robust Sensitivity: Exhibits high sensitivity, enabling detection of subtle changes in LncRNA expression.
• Unparalleled Accuracy: Ensures highly accurate measurements, facilitating reliable and reproducible data.
• Tailored Solutions: Can be customized to meet specific research demands, enhancing adaptability.

LncRNA qPCR Arrays Product List

Application

LncRNA qPCR Arrays from Creative Biogene leverage advanced technologies, sophisticated equipment, and highly experienced staff to offer unparalleled technical advantages. These arrays, compatible with 96- or 384-well qPCR formats, provide a comprehensive solution for analyzing long non-coding RNAs (lncRNAs). Their high specificity, reliability, and reproducibility, even with minimal samples, make them a powerful tool for understanding gene expression regulation at transcriptional and post-transcriptional levels. The application of LncRNA qPCR Arrays extends to diverse areas:

• Signaling Pathways: Comprehensive profiling of lncRNAs involved in various signaling pathways, facilitating the understanding of their regulatory roles in cellular processes.
• Neurodegenerative Diseases Pathways: Specialized array targeting lncRNAs associated with neurodegenerative diseases, aiding in deciphering their involvement and potential as biomarkers.
• Mental Disorders Pathways: Exploration of lncRNAs linked to mental disorders, offering insights into their regulatory functions and potential implications in psychiatric conditions.
• Autoimmune Diseases Pathways: Profiling lncRNAs relevant to autoimmune diseases, providing a tool for unraveling their roles in immune dysregulation and disease progression.
• Cancer Diseases Pathways: Targeted array for lncRNAs implicated in cancer-related pathways, aiding researchers in identifying potential biomarkers and therapeutic targets.
• Pharmacological Pathways: Investigation of lncRNAs associated with pharmacological pathways, contributing to the understanding of their impact on drug responses and development.
• Personalized Pathways: Customized array allowing researchers to focus on specific pathways of interest, enabling personalized exploration of lncRNA involvement in diverse biological processes.

Case Study

Case Study 1

The researcher utilized LncRNA qPCR Arrays Targeting Signaling Pathways to explore the functional role of thymopoietin antisense transcript 1 (TMPO-AS1) in endocrine therapy-resistant breast cancer. Leveraging RNA-sequencing data from The Cancer Genome Atlas, TMPO-AS1 was identified as a crucial modulator correlating significantly with proliferative biomarkers. In situ hybridization confirmed TMPO-AS1's association with poor prognosis in breast cancer patients. Subsequent experiments, including gain and loss of TMPO-AS1, demonstrated its promotion of proliferation and viability in estrogen receptor-positive breast cancer cells both in vitro and in vivo. Microarray analysis unveiled TMPO-AS1's close association with the estrogen signaling pathway, revealing a potential mechanism wherein TMPO-AS1 positively regulates estrogen receptor 1 (ESR1) mRNA expression. This discovery sheds new light on the molecular mechanisms driving hormone-dependent breast cancer progression and endocrine resistance.

Figure 1. In the experimental methodology, the repression of estrogen signaling and proliferation-related gene expression was investigated through TMPO-AS1 knockdown. Microarray results, as illustrated in clustering analyses, provided insights into the impact of control and TMPO-AS1-specific siRNA treatments on gene expression patterns in MCF-7 cells. (Mitobe Y, et al., 2019)

Case Study 2

Long non-coding RNAs (lncRNAs) are integral to E2F1-controlled gene networks, yet their role in advanced or treatment-resistant malignancies remains unclear. Using high-throughput transcriptomics, bioinformatics, and structural modeling, the study identified E2F1-responsive lncRNA-SLC16A1-AS1 and its associated gene SLC16A1/MCT1 as crucial for cancer invasiveness. The researcher employed LncRNA qPCR Arrays to probe their implication in advanced bladder cancer. Comprehensive functional analyses, including RNA immunoprecipitation, revealed the intricate mechanisms by which E2F1-induced lncRNA-SLC16A1-AS1 collaborates with its transcription factor, orchestrating cancer metabolic reprogramming. This program promotes a hybrid oxidative phosphorylation/glycolysis cell phenotype, fostering aggressive behavior in bladder cancer.

Figure 2. Discovery of targets and pathways linked to SLC16A1-AS1 in invasive bladder cancer. GSEA analysis of genes differentially expressed in RT-4. SLC16A1-AS1 or UMUC-3-KO mRNA microarrays reveals activation of hypoxia (top) and TNFα signaling via NFκB (bottom) upon SLC16A1-AS1 addition, contrasting with their suppression upon SLC16A1-AS1 knockout in bladder cancer. (Logotheti S, et al., 2020)

Case Study 3

Researchers utilized lncRNA qPCR microarray to analyze pancreatic ductal adenocarcinoma and adjacent tissues from 8 Chinese patients. They identified 3352 significantly differentially expressed lncRNAs, revealing unique expression patterns among individuals. Dysregulated lncRNAs were associated with key pathways in cancer biology. Co-expression network analysis highlighted potential interactions between 80 lncRNAs and 105 mRNAs. Seven markedly dysregulated lncRNAs were experimentally verified. The study provides a comprehensive view of dysregulated lncRNAs and their co-regulation networks in pancreatic ductal adenocarcinoma, suggesting their potential as biomarkers for early diagnosis, prognosis, and treatment evaluation.

Figure 3. The microarray detected 63,431 lncRNAs, visually represented in a volcano plot and quantified in whisker plots. Interestingly, the median number of detected lncRNAs showed similarity between PDAC and noncancerous tissues across individuals. (Hao S, et al., 2018)

FAQ